22.30

2.64% -0.535

Ultragenyx Pharmaceutical Inc (RARE)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché RARE Giù? Forum Previsione Frazionamento azionario

Precedente Chiudi:

$22.84

Aprire:

$22.78

Volume 24 ore:

174.05K

Relative Volume:

0.07

Capitalizzazione di mercato:

$2.16B

Reddito:

$610.16M

Utile/perdita netta:

$-532.93M

Rapporto P/E:

-4.0344

EPS:

-5.5287

Flusso di cassa netto:

$-442.30M

1 W Prestazione:

+2.00%

1M Prestazione:

-6.88%

6M Prestazione:

-28.80%

1 anno Prestazione:

-41.99%

Intervallo 1D:

$22.14

$22.84

Intervallo di 1 settimana:

$20.61

$23.19

Portata 52W:

$18.41

$42.37

Ultragenyx Pharmaceutical Inc Stock (RARE) Company Profile

Nome

Ultragenyx Pharmaceutical Inc

Settore

Healthcare (1117)

Industria

Biotechnology (618)

Telefono

415-483-8800

Indirizzo

60 LEVERONI COURT, NOVATO, CA

Dipendente

1,371

Cinguettio

Prossima data di guadagno

2024-11-05

Ultimi documenti SEC

RARE's Discussions on Twitter

Compare RARE vs VRTX, REGN, ARGX, ALNY, ONC

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
RARE Ultragenyx Pharmaceutical Inc	22.30	2.21B	610.16M	-532.93M	-442.30M	-5.5287
VRTX Vertex Pharmaceuticals Inc	494.51	126.81B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	774.86	81.62B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	733.72	45.97B	4.16B	1.29B	734.26M	19.59
ALNY Alnylam Pharmaceuticals Inc	318.98	42.76B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	301.01	33.88B	5.36B	287.73M	924.18M	2.5229

Ultragenyx Pharmaceutical Inc Stock (RARE) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2025-10-20	Iniziato	Wells Fargo	Overweight
2025-07-28	Ripresa	H.C. Wainwright	Buy
2025-05-28	Iniziato	William Blair	Outperform
2024-06-06	Aggiornamento	Goldman	Neutral → Buy
2024-04-22	Iniziato	RBC Capital Mkts	Outperform
2023-12-08	Iniziato	Wells Fargo	Overweight
2023-06-14	Ripresa	Credit Suisse	Outperform
2023-06-06	Aggiornamento	Evercore ISI	In-line → Outperform
2023-04-26	Iniziato	Cantor Fitzgerald	Overweight
2023-01-18	Ripresa	Canaccord Genuity	Buy
2022-12-30	Ripresa	H.C. Wainwright	Buy
2022-11-03	Aggiornamento	Robert W. Baird	Neutral → Outperform
2022-10-13	Aggiornamento	Guggenheim	Neutral → Buy
2022-08-01	Downgrade	Evercore ISI	Outperform → In-line
2022-03-16	Aggiornamento	Credit Suisse	Neutral → Outperform
2022-02-11	Aggiornamento	JP Morgan	Neutral → Overweight
2021-09-30	Iniziato	H.C. Wainwright	Buy
2021-08-19	Iniziato	UBS	Sell
2021-07-15	Iniziato	Guggenheim	Neutral
2021-06-29	Aggiornamento	BofA Securities	Neutral → Buy
2021-06-04	Ripresa	Robert W. Baird	Neutral
2021-05-06	Aggiornamento	Citigroup	Neutral → Buy
2021-05-06	Aggiornamento	Evercore ISI	In-line → Outperform
2021-04-26	Ripresa	Credit Suisse	Neutral
2021-03-02	Ripresa	Stifel	Buy
2021-02-12	Downgrade	JP Morgan	Overweight → Neutral
2020-12-07	Downgrade	Wedbush	Outperform → Neutral
2020-11-24	Ripresa	Evercore ISI	In-line
2020-11-12	Downgrade	BofA Securities	Buy → Neutral
2019-08-02	Ripresa	Wedbush	Outperform
2019-03-27	Aggiornamento	Morgan Stanley	Equal-Weight → Overweight
2019-02-22	Ripresa	Raymond James	Outperform
2019-01-02	Downgrade	Raymond James	Outperform → Mkt Perform
2018-11-08	Aggiornamento	Citigroup	Sell → Neutral
2018-09-10	Iniziato	Morgan Stanley	Equal-Weight
2018-06-21	Downgrade	Credit Suisse	Outperform → Neutral
2018-05-11	Aggiornamento	Barclays	Equal Weight → Overweight
2018-05-10	Iniziato	Goldman	Neutral
2018-04-18	Aggiornamento	SunTrust	Hold → Buy
2018-03-22	Ripresa	Piper Jaffray	Overweight
2018-02-21	Reiterato	Stifel	Buy
2018-01-22	Aggiornamento	Evercore ISI	In-line → Outperform
2018-01-18	Iniziato	Credit Suisse	Outperform
2017-12-05	Reiterato	Barclays	Equal Weight
2017-12-04	Aggiornamento	Jefferies	Hold → Buy
2017-09-14	Aggiornamento	Wedbush	Neutral → Outperform

Mostra tutto

Ultragenyx Pharmaceutical Inc Borsa (RARE) Ultime notizie

12:07 PM

Insider Sell: Karah Parschauer Sells Shares of Ultragenyx Pharma - GuruFocus

12:07 PM

Mar 10, 2026

RARE Investors Have Opportunity to Lead Ultragenyx - GlobeNewswire

Mar 10, 2026

Investors who lost money on Ultragenyx Pharmaceutical Inc.(RARE) should contact The Gross Law Firm about pending Class ActionRARE - PR Newswire

Mar 10, 2026

Ultragenyx EVP Pinion sells $228k in shares - Investing.com Nigeria

Mar 10, 2026

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat

Mar 10, 2026

Mar 09, 2026

Biopharma Brass Hid Drug Trial Risks, Derivative Suit Says - Law360

Mar 09, 2026

RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit - Financial Times

Mar 09, 2026

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Ultragenyx - GlobeNewswire

Mar 09, 2026

Levi & Korsinsky, LLP: Institutional Investor Notice --- Ultragenyx Pharmaceutical Lead Plaintiff Opportunity - GlobeNewswire

Mar 09, 2026

Ultragenyx Pharmaceutical (NASDAQ:RARE) Shares Up 5.6%Still a Buy? - MarketBeat

Mar 09, 2026

Portnoy Law Firm Announces Class Action on Behalf of Ultragenyx Pharmaceutical, Inc. Investors - GlobeNewswire

Mar 09, 2026

FinancialContentUltragenyx Pharmaceutical Inc. (RARE) Class Action Lawsuit Seeks Recovery for Investors; April 6, 2026, DeadlineContact Kessler Topaz Meltzer & Check, LLP - FinancialContent

Mar 09, 2026

Lead Plaintiff Deadlines in Shareholder Class Action Lawsuits Against Richtech Robotics Inc. (RR), Ultragenyx Pharmaceutical Inc. (RARE), and Mereo BioPharma Group plc (MREO) Announced by Holzer & Holzer, LLC - marketscreener.com

Mar 09, 2026

Mar 08, 2026

CLASS ACTION INVESTOR ALERTS: Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Ultragenyx and Mereo BioPharma and Encourages Investors to Contact the Firm - GlobeNewswire Inc.

Mar 08, 2026

RARE Investor Alert: Kessler Topaz Meltzer & Check, LLP Encourages RARE Investors with Losses to Contact the Firm - Financial Times

Mar 08, 2026

Mar 07, 2026